This study demonstrated the long-term efficacy of mepolizumab, a monoclonal interleukin-5 antibody, in reducing asthma exacerbations, steroid dependence, and nasal polyps over a 3-year period. Mepolizumab (MEP) is a monoclonal antibody that acts against interleukin (IL)-5 to control the proliferation, maturation, and activity of eosinophils. The efficacy of MEP in patients with severe asthma has...